% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hemminki:299557,
      author       = {K. Hemminki$^*$ and F. Zitricky},
      title        = {{V}isual presentation of age differences in relative
                      survival of hematological neoplasms in {S}weden and the
                      neighboring countries.},
      journal      = {Annals of hematology},
      volume       = {104},
      number       = {3},
      issn         = {0939-5555},
      address      = {New York},
      publisher    = {Springer},
      reportid     = {DKFZ-2025-00501},
      pages        = {1985-1993},
      year         = {2025},
      note         = {2025 Mar;104(3):1985-1993 / #EA:C020#EA:Z999},
      abstract     = {For many hematological malignancies (HMs) survival among
                      older patients is compromised. We want to test the most
                      up-to-date age-group-specific survival differences in five
                      hematological malignancies, Hodgkin lymphoma (HL), multiple
                      myeloma (MM), chronic lymphocytic leukemia (CLL), acute
                      myeloid leukemia (AML) and myeloproliferative diseases (MPD)
                      in Sweden (SE) and compared these to Denmark, Finland and
                      Norway. For analysis we apply a recently published metric
                      for comparing and visualizing age-group-specific relative
                      survival differences using data from the NORDCAN database
                      between 1972 and 2021. Periodic changes in age-related
                      deviation in SE survival showed increasing differences for
                      AML and MM while for the other HMs the differences declined
                      in the course of time. Country-specific differences were
                      observed, for Finnish male CLL and female MPD deviations
                      were larger than those for the other countries, both of
                      which were explained by the deviant survival of the oldest
                      patients. Age-related deviations in 5-year survival
                      increased for AML and MM for which survival improvements
                      have been achieved through intense treatment regimens but
                      these are not offered to old patients because of risk of
                      complications. Paradoxically, improving overall survival in
                      AML and MM has contributed to the widening of the age gaps.
                      For the remaining HMs, age-related deviations declined with
                      time as even old patients benefitted from the survival
                      improvements; most notably female MPD and CLL patients had
                      hardly any age gaps. Age disparities are an issue in
                      hematological malignancies, and an intense search for novel
                      treatments also includes old patients with an example of
                      success as a novel drug venetoclax.},
      keywords     = {Cancer registry (Other) / Periodic survival (Other) /
                      Prognosis (Other) / Treatment (Other)},
      cin          = {C020 / Z999},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331 / I:(DE-He78)Z999-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40047911},
      doi          = {10.1007/s00277-025-06291-4},
      url          = {https://inrepo02.dkfz.de/record/299557},
}